Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2016, Vol. 45 Issue (6): 655-660    DOI: 10.3785/j.issn.1008-9292.2016.11.16
综述     
糖皮质激素受体信号通路在膀胱癌治疗中的作用研究进展
封盛1,2, 陈继军2, 郑一春2
1. 浙江中医药大学附属第一医院泌尿外科, 浙江 杭州 310006;
2. 浙江大学医学院附属第二医院泌尿外科, 浙江 杭州 310009
Research progress on the effect of glucocorticoid receptor signaling pathways in bladder cancer
FENG Sheng1,2, CHEN Jijun2, ZHENG Yichun2
1. Department of Urology, the First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou 310006, China;
2. Department of Urology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
 全文: PDF(1046 KB)  
摘要：

糖皮质激素受体（GR）是核受体家族中的一员，结合配体后的受体会从细胞质中转位进入细胞核，通过对相关基因转录信号的调控发挥生物学作用。临床上，使用糖皮质激素产生的治疗效果和不良反应几乎都是通过GR信号通路实现的。越来越多的研究表明，GR信号通路与膀胱癌的增殖、侵袭性和预后密切相关，而新一代GR选择性激动剂在提升糖皮质激素抗肿瘤作用的基础上，大大减少了不良反应，有望成为膀胱癌治疗的新方法。
关键词： 膀胱肿瘤/药物疗法;  受体;  糖皮质激素/治疗应用;  信号传导;  转录;  遗传;  综述    
Abstract:

Glucocorticoid receptor (GR) is identified as a member of nuclear receptor family. To exert its biological action, the ligand bound GR is translocated from the cytoplasm into the nucleus by regulating transcriptional signals of related genes. In clinical practice, the effects of glucocorticoid are often mediated by GR signaling pathways. An increasing number of studies have indicated that GR signaling pathways play an essential role in the proliferation, invasion and prognosis of bladder cancer. Meanwhile, the new-generation selective GR activator improves its anti-tumor effects, and at the same time reduces the adverse reactions of hormones, which probably raises the prospect for the treatment of bladder cancer.
Key words: Urinary bladder neoplasms/drug therapy    Receptors, glucocorticoid/therapeutic use    Signal transduction    Transcription, genetic    Review
收稿日期: 2016-06-20
CLC:  R737.14  
基金资助:

国家自然科学基金（81202022）；浙江省自然科学基金（LY16H160028）
通讯作者: 郑一春(1977-),男,博士,副主任医师,硕士生导师,主要从事类固醇激素与泌尿系统肿瘤研究;E-mail:zhengyichun@yeah.net;http://orcid.org/0000-0001-5158-0314     E-mail: zhengyichun@yeah.net
作者简介: 封盛(1990-),男,硕士研究生,主要从事类固醇激素与泌尿系统肿瘤研究;E-mail:fengsheng_092x@163.com;http://orcid.org/0000-0002-2591-9705
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　

引用本文:

封盛 等. 糖皮质激素受体信号通路在膀胱癌治疗中的作用研究进展[J]. 浙江大学学报（医学版）, 2016, 45(6): 655-660.

FENG Sheng, CHEN Jijun, ZHENG Yichun. Research progress on the effect of glucocorticoid receptor signaling pathways in bladder cancer. Journal of ZheJiang University(Medical Science), 2016, 45(6): 655-660.

链接本文:

http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2016.11.16    或    http://www.zjujournals.com/xueshu/med/CN/Y2016/V45/I6/655

[1] CHALASANI V, CHIN J L, IZAWA J I. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer[J]. Can Urol Assoc J, 2009, 3(6 Suppl 4):S193-S198.
[2] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1):5-29.
[3] SUN M, TRINH Q D. Diagnosis and staging of bladder cancer[J]. Hematol Oncol Clin North Am, 2015, 29(2):205-218, vii.
[4] LESOVAYA E, YEMELYANOV A, SWART A C, et al. Discovery of compound A-a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity[J]. Oncotarget, 2015, 6(31):30730-30744.
[5] SIONOV R V, SPOKOINI R, KFIR-ERENFELD S, et al. Chapter 6 Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis[M]//Advances in cancer research (volume 101). New York:Academic Press, 2008:127-248.
[6] BASCH E, PRESTRUD A A, HESKETH P J, et al. Antiemetics:American Society of Clinical Oncology clinical practice guideline update[J]. J Clin Oncol, 2011, 29(31):4189-4198.
[7] ZHENG Y, IZUMI K, LI Y, et al. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals[J]. Mol Cancer Ther, 2012, 11(12):2621-2632.
[8] ISHIGURO H, KAWAHARA T, ZHENG Y, et al. Differential regulation of bladder cancer growth by various glucocorticoids:corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity[J]. Cancer Chemother Pharmacol, 2014, 74(2):249-255.
[9] ZHENG Y, ISHIGURO H, IDE H, et al. Compound A inhibits bladder cancer growth predominantly via glucocorticoid receptor transrepression[J]. Mol Endocrinol, 2015, 29(10):1486-1497.
[10] NICOLAIDES N C, CHARMANDARI E, CHROUSOS G P, et al. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids:novel mutations, circadian rhythm and ligand-induced repression of the human glucocorticoid receptor[J]. BMC Endocr Disord, 2014, 14:71.
[11] ENCÍO I J, DETERA-WADLEIGH S D. The genomic structure of the human glucocorticoid receptor[J]. J Biol Chem, 1991, 266(11):7182-7188.
[12] ZHOU J, CIDLOWSKI J A. The human glucocorticoid receptor:one gene, multiple proteins and diverse responses[J]. Steroids, 2005, 70(5-7):407-417.
[13] MCBETH L, GRABNAR M, SELMAN S, et al. Involvement of the androgen and glucocorticoid receptors in bladder cancer[J]. Int J Endocrinol, 2015, 2015:384860.
[14] MCBETH L, NWANERI A C, GRABNAR M, et al. Glucocorticoid receptor beta increases migration of human bladder cancer cells[J]. Oncotarget, 2016, 7(19):27313-27324.
[15] GIGUÉRE V, HOLLENBERG S M, ROSENFELD M G, et al. Functional domains of the human glucocorticoid receptor[J]. Cell, 1986, 46(5):645-652.
[16] DAVIES T H, NING Y M, SÁNCHEZ E R. A new first step in activation of steroid receptors:hormone-induced switching of FKBP51 and FKBP52 immunophilins[J]. J Biol Chem, 2002, 277(7):4597-4600.
[17] PRATT W B, GALIGNIANA M D, MORISHIMA Y, et al. Role of molecular chaperones in steroid receptor action[J]. Essays Biochem, 2004, 40:41-58.
[18] GRAD I, PICARD D. The glucocorticoid responses are shaped by molecular chaperones[J]. Mol Cell Endocrinol, 2007, 275(1-2):2-12.
[19] SMOAK K A, CIDLOWSKI J A. Mechanisms of glucocorticoid receptor signaling during inflammation[J]. Mech Ageing Dev, 2004, 125(10-11):697-706.
[20] AUPHAN N, DIDONATO J A, ROSETTE C, et al. Immunosuppression by glucocorticoids:inhibition of NF-kappa B activity through induction of I kappa B synthesis[J]. Science, 1995, 270(5234):286-290.
[21] AYROLDI E, RICCARDI C. Glucocorticoid-induced leucine zipper (GILZ):a new important mediator of glucocorticoid action[J]. FASEB J, 2009, 23(11):3649-3658.
[22] LESOVAYA E A, YEMELYANOV A Y, KIRSANOV K I, et al. Antitumor effect of non-steroid glucocorticoid receptor ligand CpdA on leukemia cell lines CEM and K562[J]. Biochemistry (Mosc), 2011, 76(11):1242-1252.
[23] MCKAY L I, CIDLOWSKI J A. Molecular control of immune/inflammatory responses:interactions between nuclear factor-kappa B and steroid receptor-signaling pathways[J]. Endocr Rev, 1999, 20(4):435-459.
[24] NOVAC N, BAUS D, DOSTERT A, et al. Competition between glucocorticoid receptor and NFkappaB for control of the human FasL promoter[J]. FASEB J, 2006, 20(8):1074-1081.
[25] DE BOSSCHER K, BECK I M, DEJAGER L, et al. Selective modulation of the glucocorticoid receptor can distinguish between transrepression of NF-κB and AP-1[J]. Cell Mol Life Sci, 2014, 71(1):143-163.
[26] JAFFUEL D, ROUMESTAN C, BALAGUER P, et al. Correlation between different gene expression assays designed to measure trans-activation potencies of systemic glucocorticoids[J]. Steroids, 2001, 66(7):597-604.
[27] WANG X L, HERZOG B, WALTNER-LAW M, et al. The synergistic effect of dexamethasone and all-trans-retinoic acid on hepatic phosphoenolpyruvate carboxykinase gene expression involves the coactivator p300[J]. J Biol Chem, 2004, 279(33):34191-34200.
[28] ABBINANTE-NISSEN J M, SIMPSON L G, LEIKAUF G D. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells[J]. Am J Physiol, 1995, 268(4 Pt 1):L601-L606.
[29] EHRCHEN J, STEINMVLLER L, BARCZYK K, et al. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes[J]. Blood, 2007, 109(3):1265-1274.
[30] ISHIGURO H, KAWAHARA T, ZHENG Y, et al. Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression[J]. Am J Clin Pathol, 2014, 142(2):157-164.
[31] NISHIMURA K, NONOMURA N, SATOH E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer[J]. J Natl Cancer Inst, 2001, 93(22):1739-1746.
[32] SCHLOSSMACHER G, STEVENS A, WHITE A. Glucocorticoid receptor-mediated apoptosis:mechanisms of resistance in cancer cells[J]. J Endocrinol, 2011, 211(1):17-25.
[33] AZIZ M H, SHEN H, MAKI C G. Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Cε[J]. J Biol Chem, 2012, 287(35):29825-29836.
[34] GASCOYNE D M, KYPTA R M, MD V. Glucocorticoids inhibit apoptosis during fibrosarcoma development by transcriptionally activating Bcl-xL[J]. J Biol Chem, 2003, 278(20):18022-18029.
[35] HATFIELD K J, REIKVAM H, BRUSERUD Ø. The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia[J]. Curr Med Chem, 2010, 17(36):4448-4461.
[36] HE G, KARIN M. NF-κB and STAT3-key players in liver inflammation and cancer[J]. Cell Res, 2011, 21(1):159-168.
[37] LING J, KUMAR R. Crosstalk between NF-κB and glucocorticoid signaling:a potential target of breast cancer therapy[J]. Cancer Lett, 2012, 322(2):119-126.
[38] GHOSH S, KARIN M. Missing pieces in the NF-kappaB puzzle[J]. Cell, 2002, 109 Suppl:S81-S96.
[39] YEMELYANOV A, CZWORNOG J, GERA L, et al. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells[J]. Cancer Res, 2008, 68(12):4763-4773.
[40] LESOVAYA E, YEMELYANOV A, KIRSANOV K, et al. Combination of a selective activator of the glucocorticoid receptor compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies[J]. Cell Cycle, 2013, 12(1):133-144.
[41] ZHANG L, INSEL P A. Bcl-2 protects lymphoma cells from apoptosis but not growth arrest promoted by cAMP and dexamethasone[J]. Am J Physiol Cell Physiol, 2001, 281(5):C1642-C1647.
[42] MELHEM A, YAMADA S D, FLEMING G F, et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues[J]. Clin Cancer Res, 2009, 15(9):3196-3204.
[1] 高思倩,沈咏梅,耿福能,李艳华,高建青. 颞叶癫痫与海马成体神经再生[J]. 浙江大学学报（医学版）, 2017, 46(1): 97-105.
[2] 郑艳榕,张翔南,陈忠. Nix介导的线粒体自噬机制的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 92-96.
[3] 王颖,汪仪,陈忠. 中枢胆碱能系统与癫痫关系的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 15-21.
[4] 高思倩,沈咏梅,耿福能,李艳华,高建青. 糖尿病溃疡动物模型的建立及相关治疗研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 97-105.
[5] 李文龙,瞿海斌. 近红外光谱应用于中药质量控制及生产过程监控的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 80-88.
[6] 候仕芳 等. 下调lmna基因对斑马鱼胚胎髓系和红系造血干细胞发育的影响[J]. 浙江大学学报（医学版）, 2016, 45(6): 620-625.
[7] 沈志新 等. 家族遗传性玻璃体变性混浊十例[J]. 浙江大学学报（医学版）, 2016, 45(6): 636-640.
[8] 李统宇 等. 杜氏肌营养不良疾病模型及基因治疗研究进展[J]. 浙江大学学报（医学版）, 2016, 45(6): 648-654.
[9] 夏光发 等. 新辅助化疗前后激素受体变化的乳腺癌患者辅助内分泌治疗的疗效[J]. 浙江大学学报（医学版）, 2016, 45(6): 614-619.
[10] 吴志华 等. 异基因造血干细胞移植受者T细胞受体β链CDR3谱型表达与巨细胞病毒激活[J]. 浙江大学学报（医学版）, 2016, 45(5): 515-521.
[11] 刘军 等. JAK2/STAT3信号通路介导薯蓣皂苷元对骨性关节炎软骨细胞代谢的影响[J]. 浙江大学学报（医学版）, 2016, 45(5): 453-460.
[12] 曹鹏 等. 双氢青蒿素抗肿瘤分子生物学机制研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 501-507.
[13] 李亭亭 等. 中性粒细胞在哮喘中作用的研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 544-549.
[14] 王雪 等. TANK结合激酶1在抗病毒免疫应答中的作用研究进展[J]. 浙江大学学报（医学版）, 2016, 45(5): 550-557.
[15] 何斌 等. 贝伐珠单克隆抗体在难治性子宫颈癌中的应用进展[J]. 浙江大学学报（医学版）, 2016, 45(4): 395-402.